Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis: Translating Guidelines of Care to Better Outcomes for Patients With Psoriatic Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Psoriasis
- Sponsor
- University of Pennsylvania
- Enrollment
- 520
- Locations
- 9
- Primary Endpoint
- Change in LDL
- Status
- Recruiting
- Last Updated
- 6 months ago
Overview
Brief Summary
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Detailed Description
Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Willing and able to provide informed consent
- •Male or female aged 40-75
- •Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis
Exclusion Criteria
- •Currently taking a prescription lipid lowering medication
- •Pregnant or planning pregnancy in the next 6 months
- •Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Outcomes
Primary Outcomes
Change in LDL
Time Frame: 6 months
Change in LDL cholesterol
Secondary Outcomes
- Smoking status change(6 months)
- Change in 10-year cardiovascular (CV) risk(6 months)
- Addition of new medication(6 months)
- 50% LDL reduction(6 months)
- Change in blood pressure(6 months)
- Change in cholesterol(6 months)
- Change in non-HDL(6 months)
- Change in Physicians Global Assessment (PGA) psoriasis severity(6 months)
- Change in Weight(6 months)
- 30% LDL reduction(6 months)
- LDL reduction under 100(6 months)
- Change in HDL(6 months)
- Change in HbA1c(6 months)
- Percent undergoing additional CV testing(6 months)
- Change in Body Surface Area (BSA) psoriasis severity(6 months)
- Change in physical activity days active(6 months)
- Change in dermatology life quality index (DLQI)(6 months)
- Change in physical activity level(6 months)
- Patient experience with Care Coordinator Model(6 months)
- Change in general health(6 months)
- Change in reported psoriasis medication use(6 months)